Repository navigation
Conversation
|
Claude encountered an error after 0s —— View job I'll analyze this and get back to you. |
ad572bf to
4340e5f
Compare
|
Claude finished @gingin77's task in 3m 32s —— View job Review complete — approved ✅
Verdict: approved. All 13 new guideline/paper quotes are exact, every explanation traces to the paragraph it claims (paras 57, 213, 243, 255, 279, 303, 315, 333 of Three 🔵 suggestions, none blocking: the incidental |
There was a problem hiding this comment.
Review summary
- Schema validation would pass (entity refs clean; snippet audit 195/195; snippet-grading ratchet clean)
- All references verified as real and cached (
OECDTG:442D,DOI:10.3390/toxics14040295,PMID:32335162) - Evidence snippets are exact quotes — every new snippet re-verified against the cached body with the real normalizer
- Ontology terms correct and specific (no new term bindings in this PR)
-
evidence_sourceclassifications correct - No pathophysiology bundling (no new pathophysiology nodes; this is a model-layer addition)
- Scope: 4 files, all in scope; no merge-conflict damage, no derived files
Verification run locally: just count-verified-snippets kb/disorders/Contact_Dermatitis.yaml → 195/195; just check-entity-refs → OK; just check-snippet-grading → no new divergences. I also re-checked every new snippet independently against references_cache/ with SupportingTextValidator.normalize_text — all new guideline/paper quotes are exact. The one snippet in the file that does not match its cached abstract (PMID:21742781, line 435) is pre-existing, outside this diff, and matches full text; not this PR's backlog to carry.
Content checks
The KeratinoSens citation repair is the most valuable part of this PR. The old item attributed "accepted under OECD TG 442D" to the introduction of the LuSens inter-laboratory paper. It now quotes the guideline's own VRM sentence (para 57), graded REVIEW_SYNTHESIS — the right value for a regulatory consensus document restating validation work done elsewhere.
Each new fact traces to the paragraph the explanation claims. Spot-checked against references_cache/OECDTG_442D.md:
- LuSens rat NQO1 ARE, and the direct-vs-indirect Nrf2 dependence → para 213 (the guideline's own
VMRspelling is preserved verbatim and the explanation says so).directness: INDIRECTis the right grade for a statement that the dependence is only indirectly demonstrated for this method. - Epi2SensA's two-marker prediction model and 60% viability floor → para 279; the 1 h + 5 h versus 6 h exposure likewise.
- EpiSensA/Epi2SensA VRM standing → para 243; the marker-gene arm split → the guideline's own sentence.
- α-Sens quadruplicated ARE / Luc+ / TK-Renilla → para 333; AKR1C2 identity with the VRM → same paragraph; 83% / 84% / 79% against 112 human reference substances → para 303, quoted exactly including the DASS framing.
- The limitations are not invented: "limited metabolic capability of the cell line" and the lysine-reactivity caveat are para 315 for α-Sens; the RhE "similar metabolic capacity … further confirmation is still needed" and the exposure-window point are para 255 for Epi2SensA.
The divergences do real work rather than restating fidelity. The Epi2SensA PROXY_QUANTITY entry is the right call: under a two-marker rule a positive can be carried by ATF3 + IL-8 alone, so the result does not establish that the cytoprotective arm this node carries responded — a looser proxy than EpiSensA's single-marker call. Recording that as a typed divergence rather than a procedural footnote is what the taxonomy is for. The α-Sens note that quadruplication amplifies the reporter without changing the endogenous response it stands in for is a genuine distinction from KeratinoSens's single-copy construct.
The LuSens SPECIES_MISMATCH addition is correct and correctly graded. QUALIFYING is right — the transcription factor and the pathway are the human cell's own, and only the binding site is of rat origin — and it is the one structural fact separating LuSens from the other two luciferase methods.
Scale slots are coherent. The target node Hapten-driven keratinocyte electrophile sensing is CELLULAR; Epi2SensA's TISSUE is model-above-target (unremarkable, no caveat required) and α-Sens's CELLULAR is equal. Both match how EpiSensA and KeratinoSens are already recorded, and experimental_model_type follows the neighbouring records (OTHER for RhE with the reason in notes, CELL_LINE for the luciferase methods).
The EpiSensA description fix is the right resolution, not a dodge. Saying why Keratinocyte inflammasome danger signalling is not the node for the ATF3/IL-8 arm — that node is scoped to NLRP3/ASC assembly with caspase-1, and its own notes decline to claim the proximal route — is better than either hanging the readout there or leaving "no node for this".
🔵 Suggestions (non-blocking)
references_cache/PMID_32335162.mdgains afull_text_attempted: truefrontmatter line. CLAUDE.md treats a tracked cache file modified by a validation run as a bug to report rather than a change to commit. Here the field is accurate and nothing else in the file moved, so it is harmless — but worth confirming it came from a deliberatejust fetch-referencerather than an incidental validator write-back, and dropping the hunk if it was the latter.- The α-Sens
descriptionsays it is "the only one with an internal viability control". Para 333 supports it ("allows simultaneous measurement of ARE-mediated activity and cell viability … in the same cells"), but that sentence is not among the quoted snippets. Since it is the stated reason for carrying α-Sens as a separate model, quoting it would make the claim checkable from the entry itself. - The phenyl benzoate / eugenol false-negative comparison comes from the originating paper's own abstract (correctly
IN_VITRO). A line innotesrecording that this is the developer's own comparison against the other two methods rather than an independent head-to-head would help a later reader weigh it.
Deep-research cross-check
N/A. This is a targeted augmentation of an existing entry's experimental_models block from a guideline that became citable in the base branch, not a new entry, so the new-entry deep-research requirement does not apply. The PR body's statement that Epi2SensA and α-Sens are 2026-edition appendices and therefore outside #15944's inventory is consistent with the guideline record, and the note telling whoever picks up #15944 not to re-add them is the right thing to leave behind.
Approving.
4340e5f to
f069444
Compare
|
Claude finished @gingin77's task in 2m 9s —— View job Re-review complete: approved ✅
The push was only a rebase onto I re-ran these on the rebased tree:
I submitted a new APPROVE review because the push had dropped the earlier one. The three optional 🔵 suggestions from the previous review still apply: the |
There was a problem hiding this comment.
Re-review after the rebase: approved
- Schema validation would pass
- All PMIDs verified as real (
OECDTG:442D,DOI:10.3390/toxics14040295,PMID:32335162, all cached) - Evidence snippets are exact quotes (195/195 verified against the cache)
- Ontology terms correct and specific (no new term bindings)
-
evidence_sourceclassifications correct - No pathophysiology bundling (no new pathophysiology nodes)
This push only rebased the branch onto main after #18224 merged. The PR now targets main with one commit. All four changed files have the same blob hashes as the version approved yesterday:
Contact_Dermatitis.yaml67b7495- the history record
0be61ba DOI_10.3390_toxics14040295.mda8a0a8cPMID_32335162.md9e1d6e4
So the content is identical. references_cache/OECDTG_442D.md now comes from main, so the guideline citations resolve on the base branch.
I re-ran these on the rebased tree:
just count-verified-snippets: 195/195just check-entity-refs: OKjust check-snippet-grading: no new divergences
The earlier review's three 🔵 suggestions still apply and are still optional:
- Confirm that the
full_text_attempted: trueline onPMID_32335162.mdcame from a deliberate fetch. - Quote the paragraph 333 sentence on the internal viability control for α-Sens.
- Add a note that the phenyl benzoate / eugenol comparison is the developer's own.
…deline TG 442D describes five test methods; this entry carried three. Epi2SensA and α-Sens® are now curated, and the three already here cite the guideline for their own regulatory standing rather than quoting a research paper that was only mentioning it. The replaced item is the clearest case. KeratinoSens's OECD-acceptance evidence was a `quote_role: BACKGROUND` quote from the introduction of the LuSens inter-laboratory paper — a workaround for the guideline not being citable, which attributes a regulatory statement to a study that did not make it. It now quotes the guideline's own VRM statement. LuSens and EpiSensA had no guideline citation at all and now have one each. Epi2SensA is the second RhE marker-gene method: the same four genes as EpiSensA, read in EpiDerm (EPI-200) rather than LabCyte EPI-MODEL24, with a two-marker positive call and a 60% rather than 80% viability floor. That two-marker rule is recorded as a limitation of its link, not just a procedural detail: a positive can be called on the inflammatory pair alone, so it does not establish that the cytoprotective arm the node carries responded. α-Sens® is the third ARE-Nrf2 luciferase method and the only one with an internal viability control — Firefly Luc+ under a quadruplicated AKR1C2 ARE plus TK-driven Renilla in the same cells, FBS-free. Its originating paper reports clear positives for phenyl benzoate and eugenol, which KeratinoSens or LuSens call falsely negative, which is why it is a separate model rather than a third spelling of the same one. LuSens gained a SPECIES_MISMATCH divergence. Its reporter's regulatory element is the rat NQO1 ARE read in a human cell, where the other two luciferase methods use the human AKR1C2 ARE; that was recorded only in prose. Qualifying rather than invalidating — the transcription factor and pathway are the human cell's own, and only the binding site is of rat origin. The EpiSensA link said its ATF3/IL-8 arm had no node in this entry. It now says why `Keratinocyte inflammasome danger signalling` is not that node: that node is scoped to NLRP3/ASC assembly with caspase-1 activation, and its own notes record the proximal route into the inflammasome as uncurated, so hanging a P2X7-dependent gene-induction readout there would assert the route the node declines to claim. just validate: 195 snippets, 218 titles, 0 issues. Refs #16338 Co-Authored-By: Claude Opus 5 <noreply@anthropic.com>
f069444 to
2a09a0b
Compare
|
Claude finished @gingin77's task in 34s —— View job Re-review: no new review needed, approval already on this commit ✅
This run was started by a
The three optional 🔵 suggestions from the first review still apply. None of them blocks merging:
|
|
Claude finished @gingin77's task in 23s —— View job Re-review: no new changes, approval still stands ✅
The PR head is The diff against The three optional 🔵 suggestions from the first review still apply, and none of them blocks merging:
|
TG 442D describes five test methods for keratinocyte activation. This entry carried three. Epi2SensA and α-Sens® are now curated, and the three already here cite the guideline for their own regulatory standing instead of quoting a research paper that was only mentioning it.
Stacked on #18224, which makes
OECDTG:442Dcitable. This PR's guideline citations do not resolve without it, so it targets that branch; GitHub will retarget it tomainwhen #18224 merges.The citation that was wrong
KeratinoSens's OECD-acceptance evidence was a
quote_role: BACKGROUNDquote from the introduction of the LuSens inter-laboratory paper — a workaround for the guideline not being citable, which attributes a regulatory statement to a study that did not make it. It now quotes the guideline's own validation statement. LuSens and EpiSensA had no guideline citation at all and now have one each.The two new methods
Epi2SensA is the second reconstructed-epidermis marker-gene method: the same four genes as EpiSensA, read in EpiDerm (EPI-200) rather than LabCyte EPI-MODEL24, with a two-marker positive call and a 60% rather than 80% viability floor. That two-marker rule is recorded as a limitation of its link, not just a procedural detail — a positive can be called on the inflammatory pair alone, so it does not establish that the cytoprotective arm the node carries responded.
α-Sens® is the third ARE-Nrf2 luciferase method and the only one with an internal viability control: Firefly Luc+ under a quadruplicated AKR1C2 ARE plus TK-driven Renilla in the same cells, serum-free. Its originating paper reports clear positives for phenyl benzoate and eugenol, which KeratinoSens and LuSens call falsely negative — which is why it is a separate model rather than a third spelling of the same one.
Two smaller corrections
LuSens gained a
SPECIES_MISMATCHdivergence. Its reporter's regulatory element is the rat NQO1 ARE read in a human cell, where the other two luciferase methods use the human AKR1C2 ARE. That was recorded only in prose. Qualifying rather than invalidating — the transcription factor and pathway are the human cell's own, and only the binding site is of rat origin.The EpiSensA link said its ATF3/IL-8 arm had no node in this entry. It now says why
Keratinocyte inflammasome danger signallingis not that node: that node is scoped to NLRP3/ASC assembly with caspase-1 activation, and its own notes record the proximal route into the inflammasome as uncurated, so hanging a P2X7-dependent gene-induction readout there would assert the route the node declines to claim.Relationship to #15944
Worth stating, because it is easy to misread. #15944 asks for a model inventory across in chemico, in vitro, tissue, animal and computational, and most of that list is already curated here. Epi2SensA and α-Sens® are not on it — they are appendices IC and ID of the 2026 edition of TG 442D, which postdates that issue. So this is not a slice of #15944's inventory, and it does not touch that issue's mechanistic half or its targets outside this entry.
One alignment is worth noting: #15944 asks that each model carry a stated inference, since "a reporter for one transcription factor is not the key event." The typed divergences here are that requirement made structural.
Whoever curates #15944 should not re-add these two methods.
Validation
just validate: 195 snippets, 218 titles, 0 issues. Terms pass. Ten per-file gates clean, plus the history record and the nine whole-KB ratchets.Refs #16338
🤖 Generated with Claude Code